Indication
HER2-Positive Breast Carcinoma
20 clinical trials
26 products
8 drugs
Product
RC48-ADCProduct
LapatinibClinical trial
A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-02-01
Product
CapecitabineClinical trial
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based TherapyStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Product
AnastrozoleProduct
DenifanstatProduct
ExemestaneProduct
FulvestrantProduct
LetrozoleDrug
TiragolumabDrug
TrastuzumabClinical trial
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based TherapyStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Product
RifaximinClinical trial
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-08-29
Product
Dendritic Cell VaccineProduct
Neoadjuvant ChemotherapyClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibClinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Product
CarboplatinDrug
DocetaxelProduct
PertuzumabProduct
RibociclibDrug
TucatinibClinical trial
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROGStatus: Completed, Estimated PCD: 2019-12-30
Clinical trial
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
DC1 VaccineProduct
WOKVACClinical trial
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2024-11-01
Product
NiraparibClinical trial
Single Arm Phase II Study of the Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer "TrasTUCAN Study"Status: Recruiting, Estimated PCD: 2026-08-01
Product
VinorelbineClinical trial
A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-11-20
Drug
cyclophosphamideClinical trial
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN MutationStatus: Terminated, Estimated PCD: 2022-04-29
Product
CopanlisibClinical trial
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast CancerStatus: Completed, Estimated PCD: 2022-12-22
Product
PalbociclibDrug
T-DM1Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Status: Recruiting, Estimated PCD: 2026-03-31
Drug
CeralasertibProduct
Trastuzumab DeruxtecanClinical trial
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2020-03-12
Product
NeratinibClinical trial
Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzum-Based Neoadjuvant TherapyStatus: Active (not recruiting), Estimated PCD: 2020-07-02
Clinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibStatus: Recruiting, Estimated PCD: 2028-01-01
Product
Trastuzumab EmtansineProduct
PlaceboClinical trial
Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT TrialStatus: Recruiting, Estimated PCD: 2025-03-31
Drug
CisplatinClinical trial
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31